Skip to main content
Move the World.
Coronavirus Drug

Lead Image © Lightfield Studios / Adobe Stock

An inhaled coronavirus drug has shown promise at preventing mild cases of COVID-19 from becoming more severe, according to a small new clinical trial.

Given the dire need for effective coronavirus treatments, this news is welcome — but excitement about the drug should be tempered, given the small trial size and lack of peer-review of the data.

Synairgen's Coronavirus Drug

When viruses infect cells, the cells respond by producing a protein called "interferon beta," which then coordinates their antiviral response.

The novel coronavirus, SARS-CoV-2, has been shown to stifle the production of interferon beta, leading researchers to test injections of the protein as a treatment for COVID-19.

Patients given Synairgen's coronavirus drug appeared twice as likely to recover.

U.K. biotech company Synairgen had already developed an inhalable formulation of interferon beta to treat respiratory illnesses, prior to the onset of the pandemic.

In March, the company launched a placebo-controlled, double-blind trial to test whether the drug, SNG001, could help COVID-19 patients. On July 20, it shared a press release detailing the results of that trial.

Inhalable Interferon Beta

For the trial, 101 hospitalized COVID-19 patients in the U.K. each received a dose of either Synairgen's coronavirus drug or a placebo.

During the 16-day trial period, SNG001 decreased patients' chances of becoming severely ill (for example, dying or requiring mechanical ventilation) by 79%, when compared to patients who received a placebo, according to Synairgen.

Patients who received the company's coronavirus drug also appeared to be twice as likely as those in the control group to recover from the illness, Synairgen reported (it defined "recovery" as having no signs of infection or no limitation on everyday activities).

Those in the SNG001 group also reportedly experienced a significant reduction in breathlessness, a primary symptom of severe COVID-19 cases.

"The results confirm our belief that interferon beta, a widely known drug that, by injection, has been approved for use in a number of other indications, has huge potential as an inhaled drug to be able to restore the lung's immune response, enhancing protection, accelerating recovery and countering the impact of SARS-CoV-2 virus," Tom Wilkinson, the trial's chief investigator, said in a press release.

Cautious Optimism

Though the results shared by Synairgen are encouraging, it's still far too soon to say whether the company's inhaled coronavirus drug is destined to live up to its potential.

As mentioned, the trial was small, and as it stands, Synairgen primarily findings — decreased likelihood of increased severity and better chances of recovery — just barely made the cutoff for statistical significance. Larger studies will be necessary to confirm them.

Synairgen also has yet to release the full data on the study, and when it does, that data will then need to hold up under peer review before it can be considered reliable.

We'd love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at [email protected].

Up Next

If you want to understand a problem, talk to the people working on solutions. Join us as we meet the people and explore the ideas on the frontlines of an unprecedented global response.

Public Health
The First Life-Saving Coronavirus Drug Is a Common Steroid
coronavirus drug breakthrough
Public Health
The First Life-Saving Coronavirus Drug Is a Common Steroid
A large clinical trial in the U.K. identified the cheap, widely available steroid dexamethasone as potentially the first life-saving coronavirus drug.

A large clinical trial in the U.K. identified the cheap, widely available steroid dexamethasone as potentially the first life-saving coronavirus drug.

Coronavirus
Study: Risk of Death from COVID-19 Is 45% Lower on Arthritis Drug
Risk of Death from COVID-19
Coronavirus
Study: Risk of Death from COVID-19 Is 45% Lower on Arthritis Drug
The arthritis drug tocilizumab may lower ventilated patients' risk of death from COVID-19 by 45%, according to a retrospective study.

The arthritis drug tocilizumab may lower ventilated patients' risk of death from COVID-19 by 45%, according to a retrospective study.

Public Health
Doctors Use AI to Test New Coronavirus Treatments on Patients
Coronavirus Treatments
Public Health
Doctors Use AI to Test New Coronavirus Treatments on Patients
The University of Pittsburgh Medical Center launched a new trial that uses artificial intelligence to test promising coronavirus treatments as quickly as possible.

The University of Pittsburgh Medical Center launched a new trial that uses artificial intelligence to test promising coronavirus treatments as quickly as possible.

Public Health
Antiviral Pill Shows Promise as Treatment for Coronavirus
Treatment for Coronavirus
Public Health
Antiviral Pill Shows Promise as Treatment for Coronavirus
The oral antiviral drug EIDD-2801 has emerged as a promising treatment for coronavirus, performing well in the lab and in mouse studies.

The oral antiviral drug EIDD-2801 has emerged as a promising treatment for coronavirus, performing well in the lab and in mouse studies.

Coronavirus
Moderna’s COVID-19 Vaccine Produces More Antibodies Than Infection
Moderna’s COVID-19 Vaccine
Coronavirus
Moderna’s COVID-19 Vaccine Produces More Antibodies Than Infection
Two shots of Moderna’s COVID-19 vaccine produces more antibodies than a coronavirus infection, according to Phase 1 preliminary data.

Two shots of Moderna’s COVID-19 vaccine produces more antibodies than a coronavirus infection, according to Phase 1 preliminary data.

Public Health
“That Is Insane”: The Strange, Deadly Coronavirus Immune Response
coronavirus immune response
Public Health
“That Is Insane”: The Strange, Deadly Coronavirus Immune Response
Research suggests the coronavirus immune response is different than with other viruses. It may help inform treatments and our understanding of COVID-19.

Research suggests the coronavirus immune response is different than with other viruses. It may help inform treatments and our understanding of COVID-19.

Public Health
Wearables Can Detect Coronavirus Symptoms Early
Wearables that Detect Coronavirus Symptoms
Public Health
Wearables Can Detect Coronavirus Symptoms Early
A study involving more than 600 people found that the Oura Ring wearables can detect coronavirus symptoms 72 hours prior to onset with 90% accuracy.

A study involving more than 600 people found that the Oura Ring wearables can detect coronavirus symptoms 72 hours prior to onset with 90% accuracy.

Public Health
Why Is an Antigen Test a Big Deal for COVID-19?
Antigen Test
Public Health
Why Is an Antigen Test a Big Deal for COVID-19?
The FDA has issued its first emergency use authorization for a COVID-19 antigen test, a new type of test for diagnosing the coronavirus.

The FDA has issued its first emergency use authorization for a COVID-19 antigen test, a new type of test for diagnosing the coronavirus.

Sonification
Why Scientists Are Turning the Coronavirus’ Structure Into Music
Coronavirus Structure
Sonification
Why Scientists Are Turning the Coronavirus’ Structure Into Music
MIT scientists have translated a key part of the coronavirus’ structure into music — and the song could help researchers find a way to stop the virus.

MIT scientists have translated a key part of the coronavirus’ structure into music — and the song could help researchers find a way to stop the virus.